Font Size: a A A
Keyword [anti-PD-1]
Result: 101 - 117 | Page: 6 of 6
101. Mevalonate Improves Anti-PD-1/PD-L1 Efficacy By Stabilizing PD-L1 MRNA
102. Neoadjuvant Camrelizumab Plus Apatinib Or Chemotherapy As Anti PD-1 Treatment For Stage Ⅱ-ⅢA Non-small Cell Lung Cancer
103. Circular RNA CircHMGB2 Drives Immunosuppression And Anti-PD-1 Resistance In Non-small-cell Lung Cancer Via The MiR-181a-5p/CARM1 Axis
104. Clinical Study Of Hepatic Arterial Infusion Chemotherapy Combined With Anti-PD-1 Antibody And Lenvatinib In The Treatment Of Unresectable Hepatocellular Carcinoma
105. The Role Of Inflammatory Markers In Predicting The Efficacy And Safety Of Anti-PD-1 Therapy In Advanced Non-small Cell Lung Cancer
106. Treatment-related Lymphopenia Impairs The Treatment Response Of Anti-PD-1 Therapy In Esophageal Squamous Cell Carcinoma
107. The Predictive Value Of FXR For Chemo-immunotherapy In PD-L1low/negative Non-small Cell Lung Cancer Patients
108. Experimental Study Of Gemcitabine Combined With Anti PD-1 Monoclonal Antibody In The Treatment Of Pancreatic Cancer
109. Relationship Between Cytokines Levels And Efficacy Of Anti-PD-1 Immunotherapy In Non-Small Cell Lung Cancer
110. Study On Prevention Of Recurrence Of Hepatocellular Carcinoma With Microvascular Invasion
111. Impacts Of Combining Pulsed Low Dose Rate Radiotherapy With Anti-PD-1 Antibody On Lung Cancer In Mice
112. Meta-analysis Of The Efficacy And Safety Of Anti-PD-1/PD-L1 Combined With CTLA-4 Inhibitors In The Treatment Of Solid
113. Efficacy And Safety Of Donafenib Combined With Anti-PD-1 Antibodies Plus Transarterial Therapy For Unresectable Hepatocellular Carcinoma
114. Development And Validation Of A Model To Predict Tumor Anti-PD-1/PD-L1 Therapy Related Thyroid Dysfunction
115. Prognosis Of Malignant Melanoma Of Female Genital Tract And Preliminary Evaluation Of Anti-PD-1 Therapy
116. The Impact Of Anti-PD-1 On The Immune System And The Hematopoiesis Of TNBC Mice
117. The Chromosome 11q13.3 Amplification Induces Acquired Resistance To Anti-PD-1 Antibody In Cancer Immunotherapy
  <<First  <Prev  Next>  Last>>  Jump to